Evidence map›Paper›PMID 35982947›Full record

ArticleFrontiers in oncology2022

Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in

Mythili Merchant, Margarita Raygada, Ying Pang, Martha Quezado, Mark Raffeld, Liqiang Xi, Jung Kim, Manoj Tyagi, Zied Abdullaev, Olga Kim and 9 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Mythili MerchantNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Margarita RaygadaNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Ying PangNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Martha QuezadoLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Mark RaffeldLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Liqiang XiLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Jung KimLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Manoj TyagiLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Zied AbdullaevLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Olga KimNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Zach SergiNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Tina PillaiNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Byram OzerNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Kareem ZaghloulSurgical Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, United States.
John D HeissSurgical Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, United States.
Terri S ArmstrongNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Mark R GilbertNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Kenneth AldapeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Jing WuNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
National Cancer Institute · USCenter for Cancer Research · USNational Institute of Neurological Disorders and Stroke · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most tumors, including brain tumors, are sporadic. However, a small subset of CNS tumors are associated with hereditary cancer conditions like Lynch Syndrome (LS). Here, we present a case of an oligodendroglioma, IDH-mutant and 1p/19q-codeleted, and LS with a germline pathogenic

Indexed as

CNSIDH-mutant and 1p/19q-codeletedlynch syndromeoligodendrogliomaPMS2

Identifiers

PMID35982947
PMCPMC9379095
OpenAlexW4289522510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.